In previous studies, anti-IL-6 antibody treatment was found to prevent severe LN in the BWF1 model51 while recombinant IL-6 treatment was found to accelerate disease52, demonstrating the SLE-promoting role of IL-6. Here, IL6 is linked to systemic lupus erythematosus.